We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NVTS:NASDAQNavitas Semiconductor Corporation Analysis

Data as of 2026-05-22 - not real-time

$24.38

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Navitas Semiconductor is trading at $24.38, hugging its 52‑week high of $25.20 and sitting comfortably above the 20‑day ($18.87), 50‑day ($13.80) and 200‑day ($9.94) simple moving averages, which signals a bullish technical backdrop. The RSI of 66 and a bullish MACD histogram (+0.22) confirm momentum, while rising volume supports the up‑trend; however, the stock is perched near the $25.20 resistance level and the RSI hints at overbought conditions. Fundamentally, the picture is starkly different: revenue has contracted 38.7% year‑over‑year, operating margins are negative (-3.2%), and EPS remains in the red (-$0.63 trailing, -$0.14 forward). The company’s DCF fair value of roughly $3.36 implies a 44% downside, and the price‑to‑sales ratio of 140× dwarfs industry norms, while analysts peg a median target near $13, underscoring severe overvaluation. Recent news of an 18% sequential revenue rise and a new GaN power‑device launch offers a glimpse of growth potential in AI data‑center and energy‑infrastructure markets, yet the underlying profitability challenges and extreme market greed (Fear/Greed Index 91.5) keep the risk profile elevated.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Price near resistance and overbought RSI
  • DCF valuation suggests ~44% downside
  • Very high 30‑day volatility (159%) and beta

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sequential revenue growth and new GaN product rollout
  • Continued cash cushion but negative operating cash flow
  • Uncertain path to profitability amid high valuation

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Long‑term demand from AI data‑center and energy markets
  • Large cash balance provides runway for R&D
  • Persistent earnings losses and valuation gap to DCF

Key Metrics & Analysis

Financial Health

Revenue Growth-38.70%
P/E Ratio-169.9
ROE-35.15%
ROA-12.76%
Debt/Equity1.51
P/B Ratio13.5
Op. Cash Flow$-45720000
Free Cash Flow$43.8M
Industry P/E39.1

Technical Analysis

TrendBullish
RSI66.3
Support$14.14
Resistance$25.20
MA 20$18.87
MA 50$13.80
MA 200$9.94
MACDBullish
VolumeIncreasing
Fear & Greed Index91.54

Valuation

Fair Value$3.36
Target Price$13.59
Upside/Downside-44.27%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta4.78
Volatility159.23%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.